These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38423379)

  • 1. Morindone as a potential therapeutic compound targeting TP53 and KRAS mutations in colorectal cancer cells.
    Chee CW; Mohd Hashim N; Nor Rashid N
    Chem Biol Interact; 2024 Apr; 392():110928. PubMed ID: 38423379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morindone from Morinda citrifolia as a potential antiproliferative agent against colorectal cancer cell lines.
    Chee CW; Zamakshshari NH; Lee VS; Abdullah I; Othman R; Lee YK; Mohd Hashim N; Nor Rashid N
    PLoS One; 2022; 17(7):e0270970. PubMed ID: 35819953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA Sequencing and Bioinformatics Analysis Reveals the Downregulation of DNA Replication Genes by Morindone in Colorectal Cancer Cells.
    Chee CW; Mohd Hashim N; Abdullah I; Nor Rashid N
    Appl Biochem Biotechnol; 2024 Jun; 196(6):3216-3233. PubMed ID: 37642925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Damnacanthal, a noni component, exhibits antitumorigenic activity in human colorectal cancer cells.
    Nualsanit T; Rojanapanthu P; Gritsanapan W; Lee SH; Lawson D; Baek SJ
    J Nutr Biochem; 2012 Aug; 23(8):915-23. PubMed ID: 21852088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new anthraquinone from Morinda citrifolia roots.
    Ee GC; Wen YP; Sukari MA; Go R; Lee HL
    Nat Prod Res; 2009; 23(14):1322-9. PubMed ID: 19735047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
    Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
    Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.
    He SY; Li YC; Wang Y; Peng HL; Zhou CL; Zhang CM; Chen SL; Yin JF; Lin M
    World J Gastroenterol; 2022 Jul; 28(25):2920-2936. PubMed ID: 35978873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma.
    Javier BM; Yaeger R; Wang L; Sanchez-Vega F; Zehir A; Middha S; Sadowska J; Vakiani E; Shia J; Klimstra D; Ladanyi M; Iacobuzio-Donahue CA; Hechtman JF
    Oncotarget; 2016 Aug; 7(32):50875-50882. PubMed ID: 27248473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 15. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.
    Du L; Kim JJ; Shen J; Chen B; Dai N
    Oncotarget; 2017 Mar; 8(13):22175-22186. PubMed ID: 28077799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Damnacanthal and its nanoformulation exhibit anti-cancer activity via cyclin D1 down-regulation.
    Sukamporn P; Rojanapanthu P; Silva G; Zhang X; Gritsanapan W; Baek SJ
    Life Sci; 2016 May; 152():60-6. PubMed ID: 27018445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells.
    Tamura S; Tazawa H; Hori N; Li Y; Yamada M; Kikuchi S; Kuroda S; Urata Y; Kagawa S; Fujiwara T
    PLoS One; 2023; 18(11):e0294491. PubMed ID: 37972012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.
    Liao WT; Ye YP; Zhang NJ; Li TT; Wang SY; Cui YM; Qi L; Wu P; Jiao HL; Xie YJ; Zhang C; Wang JX; Ding YQ
    J Pathol; 2014 Mar; 232(4):415-27. PubMed ID: 24293274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA‑337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways.
    Liu X; Wang Y; Zhao J
    Oncol Rep; 2017 Nov; 38(5):3187-3196. PubMed ID: 29048669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.